Samsung Biologics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Operating Revenue	5,504,838	4,547,322	3,694,589	3,001,295	1,568,007	1,164,777	Upgrade
Other Revenue	-	-	-	-0	-	-	Upgrade
Revenue	5,504,838	4,547,322	3,694,589	3,001,295	1,568,007	1,164,777	Upgrade
Revenue Growth (YoY)	26.13%	23.08%	23.10%	91.41%	34.62%	66.02%	Upgrade
Cost of Revenue	2,427,021	2,273,151	1,900,080	1,540,526	844,657	751,189	Upgrade
Gross Profit	3,077,818	2,274,171	1,794,509	1,460,769	723,350	413,588	Upgrade
Selling, General & Admin	831,092	758,510	535,421	380,456	169,630	110,009	Upgrade
Research & Development	173,756	144,649	81,588	45,884	954.22	-	Upgrade
Amortization of Goodwill & Intangibles	16,390	13,629	9,977	7,700	4,572	3,950	Upgrade
Other Operating Expenses	12,746	11,145	10,339	7,448	1,804	1,789	Upgrade
Operating Expenses	1,061,017	954,119	680,829	477,142	186,040	120,802	Upgrade
Operating Income	2,016,800	1,320,052	1,113,680	983,627	537,309	292,787	Upgrade
Interest Expense	-52,955	-50,057	-81,596	-64,064	-14,707	-16,086	Upgrade
Interest & Investment Income	52,659	63,839	95,650	53,293	9,656	13,140	Upgrade
Earnings From Equity Investments	18,094	2,660	-499.42	27,260	13,853	-17,768	Upgrade
Currency Exchange Gain (Loss)	50,425	77,140	-11,186	-63,503	17,874	-3,196	Upgrade
Other Non Operating Income (Expenses)	27,540	19,789	2,652	2,347	4,494	3.96	Upgrade
EBT Excluding Unusual Items	2,112,562	1,433,423	1,118,701	938,960	568,479	268,882	Upgrade
Gain (Loss) on Sale of Investments	1,136	597.28	5,152	72,653	269.12	303.96	Upgrade
Gain (Loss) on Sale of Assets	-2,618	-2,199	-3,866	-2,588	-7,466	-1,841	Upgrade
Asset Writedown	-61,770	-61,770	-	-	-	-1,352	Upgrade
Pretax Income	2,049,311	1,370,052	1,119,987	1,009,025	561,283	265,992	Upgrade
Income Tax Expense	453,418	286,736	262,296	210,968	167,693	25,017	Upgrade
Earnings From Continuing Operations	1,595,893	1,083,316	857,691	798,056	393,589	240,975	Upgrade
Net Income	1,595,893	1,083,316	857,691	798,056	393,589	240,975	Upgrade
Net Income to Common	1,595,893	1,083,316	857,691	798,056	393,589	240,975	Upgrade
Net Income Growth	51.63%	26.31%	7.47%	102.76%	63.33%	18.76%	Upgrade
Shares Outstanding (Basic)	46	46	46	45	43	43	Upgrade
Shares Outstanding (Diluted)	46	46	46	45	43	43	Upgrade
Shares Change (YoY)	-	-	1.95%	5.51%	-	-	Upgrade
EPS (Basic)	34475.27	23402.33	18528.27	17592.79	9146.19	5599.75	Upgrade
EPS (Diluted)	34474.63	23402.33	18528.27	17577.11	9146.19	5599.75	Upgrade
EPS Growth	51.63%	26.31%	5.41%	92.18%	63.33%	18.76%	Upgrade
Free Cash Flow	791,557	355,682	671,158	-3,792	48,343	62,425	Upgrade
Free Cash Flow Per Share	17099.61	7683.62	14498.68	-83.52	1123.38	1450.63	Upgrade
Gross Margin	55.91%	50.01%	48.57%	48.67%	46.13%	35.51%	Upgrade
Operating Margin	36.64%	29.03%	30.14%	32.77%	34.27%	25.14%	Upgrade
Profit Margin	28.99%	23.82%	23.21%	26.59%	25.10%	20.69%	Upgrade
Free Cash Flow Margin	14.38%	7.82%	18.17%	-0.13%	3.08%	5.36%	Upgrade
EBITDA	2,688,135	1,919,154	1,603,462	1,291,892	699,098	436,475	Upgrade
EBITDA Margin	48.83%	42.20%	43.40%	43.04%	44.59%	37.47%	Upgrade
D&A For EBITDA	671,335	599,101	489,782	308,264	161,789	143,688	Upgrade
EBIT	2,016,800	1,320,052	1,113,680	983,627	537,309	292,787	Upgrade
EBIT Margin	36.64%	29.03%	30.14%	32.77%	34.27%	25.14%	Upgrade
Effective Tax Rate	22.13%	20.93%	23.42%	20.91%	29.88%	9.40%	Upgrade
Advertising Expenses	-	17,042	11,916	8,829	5,349	4,396	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.